Innate Pharma (XPAR:IPH) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Change In Receivables?

Innate Pharma's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Innate Pharma's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Innate Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Innate Pharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Innate Pharma's Accounts Receivable for the quarter that ended in Dec. 2023 was €15.23 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Innate Pharma's Days Sales Outstanding for the six months ended in Dec. 2023 was 167.91.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Innate Pharma's liquidation value for the six months ended in Dec. 2023 was €-28.41 Mil.

Innate Pharma Change In Receivables Historical Data

The historical data trend for Innate Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Change In Receivables Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

110.30

-22.92

3.39

-4.20

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-3.12	-13.29	9.09	-	-

Innate Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Innate Pharma (XPAR:IPH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Innate Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.233	/	16.557	*	91
=	167.91

2. In Ben Graham's calculation of liquidation value, Innate Pharma's accounts receivable are only considered to be worth 75% of book value:

Innate Pharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	92.456	-	132.292	+	0.75 * 15.233	+	0.5 * 0
=	-28.41

Innate Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines